# Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)

> **NCT00310830** · PHASE3 · TERMINATED · sponsor: **Actelion** · enrollment: 14 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Bosentan

## Key facts

- **NCT ID:** NCT00310830
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310830, "Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00310830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*